Showing results (1-10 of 367) with videos related to
Sort By:
Pageof 37
Clinical Pharmacokinetics|January 1, 1995
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19D A FlockhartClinical Pharmacology and Therapeutics|April 20, 2012
The need for translational research on drug-drug interactionsS Hennessy, D A FlockhartClinical Pharmacology and Therapeutics|July 11, 2008
Finding the right research question: quality science depends on quality careersD A Flockhart, D R AbernethyChild and Adolescent Psychiatric Clinics of North America|February 16, 2000
Cytochrome P450-mediated drug interactionsD A Flockhart, J R OesterheldClinical Pharmacology and Therapeutics|January 23, 2014
Personal DNA donation to energize genomic medicineW J Lu, D A FlockhartClinical Pharmacology and Therapeutics|March 7, 2007
Enhancing race-based prescribing precision with pharmacogenomicsA Nguyen, Z Desta, D A FlockhartClinical Pharmacology and Therapeutics|February 10, 1999
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)Z Desta, T Kerbusch, D A FlockhartJournal of Clinical Pharmacology|December 1, 1999
Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolamR Yuan, D A Flockhart, J D BalianDrug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 1999
Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6J G Shin, N Soukhova, D A FlockhartAntimicrobial Agents and Chemotherapy|February 13, 2001
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3AZ Desta, N V Soukhova, D A FlockhartPageof 37